Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Yanyan Cao, Tao Ouyang, Fu Xiong, Xuefeng Kan, Lei Chen, Bin Liang, Chuansheng Zheng
Summary: The sequential use of apatinib treatment significantly improved overall survival in patients with unresectable hepatocellular carcinoma refractory to sorafenib-TACE. Compared to supportive care, apatinib treatment resulted in better efficacy outcomes.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu
Summary: The combination of sorafenib and radiotherapy can increase survival rates for advanced hepatocellular carcinoma patients, particularly when radiotherapy is administered after sorafenib treatment.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Zhuangzhuang Zheng, Zijing Liu, Haifeng Zhang, Xiao Guo, Xiaojing Jia, Jianfeng Wang, Lingbin Meng, Ying Xin, Xin Jiang
Summary: This study retrospectively analyzed the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC). The results showed that apatinib mesylate is an effective treatment for advanced HCC, and its adverse reactions are relatively mild.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, Atsushi Kawaguchi, Hironori Koga, Takuji Torimura
Summary: The combination of sorafenib with S-1 metronomic chemotherapy showed potential efficacy in treating advanced HCC with tolerable adverse events. Although the objective response rate was higher than sorafenib monotherapy, there were no significant differences in overall survival or time to progression. Adverse events were more common in the combination therapy group, but no patients had to discontinue treatment due to severe adverse events.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giovanni Giannini, Sara Marinelli, Gian Ludovico Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Giuseppe Foschi, Marco Zoli, Antonio Gasbarrini, Gianluca Svegliati Baroni, Alberto Masotto, Rodolfo Sacco, Giovanni Raimondo, Francesco Azzaroli, Andrea Mega, Gianpaolo Vidili, Maurizia Rossana Brunetto, Gerardo Nardone, Luigina Vanessa Alemanni, Elton Dajti, Federico Ravaioli, Davide Festi, Franco Trevisani
Summary: This study aimed to identify simple demographic and clinical parameters to predict survival and Sorafenib response in patients with advanced hepatocellular carcinoma. The results showed that patient's general status, liver function, laboratory parameters, and HCC aggressiveness were associated with the outcome of Sorafenib therapy. Two predictive nomograms were created to assist clinicians in therapeutic choices.
Article
Medicine, General & Internal
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Summary: This study evaluated the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma, showing no significant differences in outcomes between younger and older patients. Age alone should not restrict clinical decision-making for patients with advanced HCC.
Review
Oncology
Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang, Bo Li
Summary: This meta-analysis compares the efficacy and safety of lenvatinib and sorafenib in patients with advanced hepatocellular carcinoma (HCC). The results showed that lenvatinib had significantly better progression-free survival and disease control rate compared to sorafenib, with similar incidences of adverse events. Lenvatinib is a promising alternative to sorafenib as a first-line therapy for advanced HCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liyun Zheng, Shiji Fang, Fazong Wu, Weiqian Chen, Minjiang Chen, Qiaoyou Weng, Xulu Wu, Jingjing Song, Zhongwei Zhao, Jiansong Ji
Summary: The study compared the efficacy and safety of TACE+Sor group and TACE+Sor+ICIs group in treating intermediate and advanced TACE-refractory HCC, showing that TACE+Sor+ICIs group had a higher disease control rate and prolonged PFS and OS.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang
Summary: This study showed that regorafenib has comparable effectiveness and safety to the RESORCE trial for hepatocellular carcinoma patients. Regorafenib improves the prognosis of patients with prolonged TTP during previous sorafenib therapy.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Medicine, General & Internal
Shou-Wu Lee, Sheng-Shun Yang, Han-Chung Lien, Yen-Chun Peng, Chung-Wang Ko, Teng-Yu Lee
Summary: This study found that Taiwanese patients with advanced-stage HCC who received lenvatinib had better objective response rate and disease control rate compared to those who received sorafenib. Patients with an objective tumor response had a better overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
Summary: This study demonstrated that avelumab had moderate efficacy and good tolerability in patients with advanced hepatocellular carcinoma previously treated with sorafenib. The duration of sorafenib treatment prior to avelumab therapy appeared to influence the treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Xiao-Hui Wang, Wei Liang, Hui Li, Xiao-Yan Xie, Shao-Qiang Li, Min-Shan Chen, Ping Liang, Xian-Hai Mao, Qun-Fang Zhou
Summary: This study aimed to evaluate the efficacy of radiofrequency ablation (RFA) following transarterial chemoembolisation (TACE) and sorafenib for intermediate-stage recurrent hepatocellular carcinoma (RHCC). The results showed that the combination of TACE, sorafenib, and RFA resulted in higher overall survival (OS) and progression-free survival (PFS) rates compared to TACE and sorafenib alone.
Article
Gastroenterology & Hepatology
Razwan A. Razak, Peter Fletcher, Victoria Kunene, Yuk Ting Ma
Summary: In contrast to patients with non-small cell lung cancer and renal cell carcinoma, patients with advanced hepatocellular carcinoma who coadminister gastric acid suppressants and sorafenib exhibit significantly inferior outcomes in terms of progression-free survival and overall survival.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2021)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann-Lii Cheng, Andrew X. Zhu
Summary: This study reports the long-term efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with advanced hepatocellular carcinoma. The results demonstrate durable anti-tumor activity of pembrolizumab in these patients, with a favorable safety profile.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Nynne Emilie Hummelshoj, Henning Gronbaek, Palle Bager, Elizaveta Tabaksblat, Gitte Dam
Summary: This study investigated the health-related quality of life (HRQoL) and fatigue levels in out-patients with Neuroendocrine Neoplasms (NEN). The results showed that patients had lower HRQoL and higher levels of fatigue compared to the general population. Specifically, patients with carcinoid syndrome experienced pain, discomfort, anxiety, and depression along with a decrease in HRQoL.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Marika Rudler, Virginia Hernandez-Gea, Bogdan Dumitru Procopet, Alvaro Giraldez, Lucio Amitrano, Candid Villanueva, Luis Ibanez, Gilberto Silva-Junior, Joan Genesca, Christophe Bureau, Jonel Trebicka, Rafael Banares, Aleksander Krag, Elba Llop, Wim Laleman, Jose Maria Palazon, Jose Castellote, Susana Rodrigues, Lise Lotte Gluud, Carlos Noronha Ferreira, Nouria Canete, Manuel Rodriguez, Arnulf Ferlitsch, Jose Luis Mundi, Henning Gronbaek, Manuel Hernandez-Guerra, Romano Sassatelli, Alessandra Dell'era, Marco Senzolo, Juan G. Abraldes, Manuel Romero-Gomez, Alexander Zipprich, Meritxell Casas, Helena Masnou, Helene Larrue, Massimo Primignani, Frederik Nevens, Jose Luis Calleja, Remy Schwarzer, Christian Jansen, Marie-Angele Robic, Irene Conejo, Javier Martinez Gonzalez, Maria Vega Catalina, Agustin Albillos, Edilmar Alvarado, Maria Anna Guardascione, Maxime Mallet, Simona Tripon, Georgina Casanovas, Jaume Bosch, Juan-Carlos Garcia-Pagan, Dominique Thabut
Summary: pTIPS is more effective in improving survival compared to endoscopic treatment for high-risk patients with cirrhosis and variceal bleeding. HE at admission does not affect the efficacy of pTIPS.
Article
Oncology
Morten Ladekarl, Anne Krogh Nohr, Mads Sonderkaer, Simon Christian Dahl, Lone Sunde, Charles Vestereghem, Christophe Kamungu Mapendano, Charlotte Aaquist Haslund, Anja Pagh, Andreas Carus, Tamas Lorincz, Kinga Nowicka-Matus, Laurids O. Poulsen, Rene Johannes Laursen, Karen Dybkaer, Birgitte Klindt Poulsen, Jens Brondum Frokjaer, Anja Hoegh Brugmann, Anja Ernst, Alkwin Wanders, Martin Bogsted, Inge Sokilde Pedersen
Summary: The aim of this study was to describe a precision medicine program in a regional academic hospital, including the characteristics of the patients and the early data on clinical impact. The results showed that molecular profiling identified potential targets for treatment in a significant number of late-stage cancer patients, with a higher chance of targeted treatment for those with a history of cancer among 1st degree relatives and a diagnosis of lung or prostate cancer.
Editorial Material
Gastroenterology & Hepatology
Karen L. Thomsen, Henning Gronbaek
Summary: This article is linked to the paper by Chalin et al. To view this article, please visit the link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Tina Kringelbach, Martin Hojgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harslof, Laila Belcaid, Julie Gehl, Lise Sondergaard, Rikke Lovendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen
Summary: The ProTarget trial aims to investigate the anti-tumor activity and toxicity of commercially available targeted therapies in cancer patients with specific actionable genomic alterations. This national trial will provide new data and insights into molecular pathways and potentially expand personalized cancer treatment strategies.
Article
Oncology
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Soenke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Summary: This study aims to investigate whether reduced dose GemNab is superior to full dose Gem in patients with resectable pancreatic cancer. The study will explore various endpoints including progression-free survival, overall survival, overall response rate, quality of life, toxicity, and rate of hospitalizations. The correlation between blood inflammatory markers, circulating tumor DNA, tissue biomarkers, and chemotherapy resistance will also be studied, along with measures of frailty to assess personalized treatment allocation or interventions.
Article
Gastroenterology & Hepatology
Matthias Egger, Angela Horvath, Florian Prueller, Peter Fickert, Malcolm Finkelman, Lisa Kriegl, Henning Gronbaek, Holger Jon Moller, Juergen Prattes, Robert Krause, Martin Hoenigl, Vanessa Stadlbauer
Summary: Liver cirrhosis, a systemic disease causing 1 million deaths per year, is associated with fungal translocation and its effects on gut integrity, inflammation, and liver disease severity/outcome. This study found a correlation between fungal translocation and markers of gut inflammation, as well as a significant difference in mortality between patients with positive versus negative fungal translocation. Further research is needed to understand the complex interactions and potential therapeutic interventions.
LIVER INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Editorial Material
Oncology
Morten Ladekarl
CHINESE CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jakob Kirkegard, Morten Ladekarl, Andrea Lund, Frank Mortensen
Summary: This study examined the impact of early versus late initiation of adjuvant chemotherapy on pancreatic adenocarcinoma survival. The results showed that postponing chemotherapy up to 8 weeks after discharge is safe and may allow more patients to receive adjuvant therapy and have better recovery.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Siren Morken, Seppo W. Langer, Anna Sundlov, Lene Weber Vestermark, Morten Ladekarl, Geir Olav Hjortland, Johanna B. Svensson, Elizaveta Mitkina Tabaksblat, Torjan Magne Haslerud, Jorg Assmus, Sonke Detlefsen, Anne Couvelard, Aurel Perren, Halfdan Sorbye
Summary: This study evaluated the efficacy and safety of everolimus and temozolomide as first-line treatment for metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. The results showed that this treatment option can effectively control the disease and prolong progression-free survival and overall survival. The treatment response was better in NET G3 patients, but there were some toxicities reported.
BRITISH JOURNAL OF CANCER
(2023)
Article
Endocrinology & Metabolism
Karen Kristina Nyvold Johnson, Tobias Stemann Lau, Simon Mark Dahl Baunwall, Gerda Elisabeth Villadsen, Vibeke Guldbrand Rasmussen, Henning Gronbaek, Riina Karoliina Oksjoki, Gitte Dam
Summary: Our study investigated NT-proBNP, CgA, and P-5-HIAA as screening tools for detecting Carcinoid heart disease (CHD). The results showed that CgA and P-5-HIAA are excellent markers of CHD, while NT-proBNP lacks the required diagnostic accuracy to be used as a screening tool.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Oncology
Mette T. Mouritzen, Morten Ladekarl, Henrik Hager, Trine B. Mattesen, Julie B. Lippert, Malene S. Frank, Anne K. Nohr, Ida B. Egendal, Andreas Carus
Summary: This study aimed to assess the association of gene expressions, blood immune cell counts, and clinical characteristics with durable clinical benefit of immunotherapy in advanced non-small cell lung cancer. The results showed that high absolute lymphocyte count and absence of liver metastases were significantly associated with durable clinical benefit. Gene expression profiling revealed differentially expressed genes associated with clinical benefit, and PD-L1 could be assessed by gene expression profiling instead of immunohistochemistry.
Article
Surgery
Jakob Kirkegard, Morten Ladekarl, Ida Ravnsbaek Johannsen, Frank Mortensen
Summary: This study aimed to evaluate the effect of adjuvant chemotherapy on survival in patients with node-negative pancreatic cancer after surgery using target trial emulation. The findings suggest that adjuvant chemotherapy does not improve survival in patients with node-negative pancreatic cancer.
BRITISH JOURNAL OF SURGERY
(2023)
Meeting Abstract
Endocrinology & Metabolism
C. Schalin-Jantti, M. Kjellman, U. Knigge, H. Gronbaek, E. Thiis-Evensen, S. Welin, H. Sorbye, M. Schneider, R. Belusa
JOURNAL OF NEUROENDOCRINOLOGY
(2022)